Literature DB >> 30153572

Persistent adverse effects following different targets and periods after bilateral deep brain stimulation in patients with Parkinson's disease.

Zixiao Yin1, Yuan Cao2, Suyue Zheng3, Jian Duan3, Dongwei Zhou3, Renxu Xu4, Tao Hong3, Guohui Lu5.   

Abstract

BACKGROUND: Performed as one of the major treatments for advanced Parkinson's disease (PD), deep brain stimulation (DBS) surgery can induce adverse effects (AEs) on cognition, gait, mood, speech and swallowing, which are frequently reported and seriously affect the patient's daily life.
OBJECTIVE: To comprehensively analysis the adverse effect rates (AERs) of cognition, mood, gait, speech and swallowing after bilateral DBS in patients with PD.
METHOD: We performed a systematic search in PubMed, EMBASE and the Cochrane Library to collect all the articles reporting AEs after DBS in sufferers of PD. The cited articles were also manually searched.
RESULTS: A total of 31 articles were quantitatively analyzed. Random-effects models were used to calculate the AERs and 95% confidence intervals. Of all patients, the pooled AER of the five types of events was 24.0%. Specifically, the risks of cognition, mood and speech disturbance were higher after subthalamic nucleus (STN) -DBS than after globus pallidus interna (GPi) -DBS: 25.1% versus 14.6%, 26.3% versus 22.2% and 29.0% versus 19.6%, respectively. However, the AER of dysphagia was slightly lower after STN-DBS: 8.6% versus 10.1%. The risk of gait disorders was similar between two target groups in sub-analysis of random control trials (RCTs): 38.3% in STN group and 37.3% in GPi group. In three follow-up intervals, short-term follow-up (STF), mid-term follow-up (MTF) and long-term follow-up (LTF), gait (17.6%~19.9%~28.0%), speech (7.8%~26.9%~31.5%) and mood (7.4%~24.9%~30.7%) disorders worsened progressively. While cognitive disturbance (22.5%~27.1%~16.7%) reached its highest rate at MTF.
CONCLUSION: STN-DBS was 10% more likely to cause cognitive and speech disturbance than GPi-DBS, while STN-DBS had a lower risk of dysphagia. Two target groups had similar effects on gait. The pooled AER increased over time, while cognitive disturbance reached its highest rate at the 6- to 18-month follow-up. Additionally, speech and mood disturbance deteriorated rapidly from STF to MTF. Further investigation of the pathophysiology will help alleviate those AEs after DBS.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adverse effects; Deep brain stimulation; Globus pallidus internus; Parkinson's disease; Subthalamic nucleus

Mesh:

Year:  2018        PMID: 30153572     DOI: 10.1016/j.jns.2018.08.016

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

Review 1.  A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies.

Authors:  Philippe A Salles; James Liao; Umar Shuaib; Ignacio F Mata; Hubert H Fernandez
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 2.  Gastrointestinal dysfunction in the synucleinopathies.

Authors:  Kathryn A Chung; Ronald F Pfeiffer
Journal:  Clin Auton Res       Date:  2020-11-27       Impact factor: 4.435

Review 3.  Autonomic Dysfunction in Parkinson's Disease.

Authors:  Ronald F Pfeiffer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

4.  Does Subthalamic Deep Brain Stimulation Impact Asymmetry and Dyscoordination of Gait in Parkinson's Disease?

Authors:  Deepak K Ravi; Christian R Baumann; Elena Bernasconi; Michelle Gwerder; Niklas K Ignasiak; Mechtild Uhl; Lennart Stieglitz; William R Taylor; Navrag B Singh
Journal:  Neurorehabil Neural Repair       Date:  2021-09-22       Impact factor: 3.919

5.  Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Xiao Dong Liu; Yi Bao; Guang Jian Liu
Journal:  Front Neurol       Date:  2019-08-27       Impact factor: 4.003

6.  Can the Executive Control Network be Used to Diagnose Parkinson's Disease and as an Efficacy Indicator of Deep Brain Stimulation?

Authors:  Wenwen Dong; Chang Qiu; Xu Jiang; Bo Shen; Li Zhang; Weiguo Liu; Wenbin Zhang; Jiu Chen
Journal:  Parkinsons Dis       Date:  2020-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.